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Abstract Objective Environmental classification systems
for medicines have been proposed. It is important that these
systems are integrated into clinical practice. Numerous
studies have shown that feedback to healthcare profes-
sionals of their prescribing patterns is effective in changing
behaviour. The aim of this study was to develop a method
to incorporate an environmental classification for medi-
cines in drug utilization data provided to prescribers. Drug
prescribing was calculated on all pharmacy sales of med-
icines in ambulatory care in Stockholm, Sweden
(1.9 million inhabitants) during 2006. Method Prescribing
profiles were generated focusing on medicines that
accounted for 90% of the volume (DU90%) of antibiotics
(ATC-group J01), drugs for musculoskeletal conditions
(NSAIDs, M01A), antihypertensive agents (C03, C07, C08
and C09) and antidepressants (N06A). The medicines in
these 90% segments were measured as kilograms of active
substance and were coded according to the classification of
environmental hazard developed by Stockholm County
Council and Apoteket AB. Main outcome measure Amount
of pharmaceuticals dispensed (kg) and the classification of
environmental hazard for the active substances accounting
for the top 90% of the total amount prescribed. Results A
total of 16,800 kg of antibiotics, 23,400 kg of NSAIDs,
7,700 kg of various antihypertensive substances and
1,700 kg of antidepressants had been dispensed in the
region, corresponding to 2.3, 3.3, 1.1 and 0.2 kg of drug
substance per square kilometre, respectively. A total of 12,
3, 13 and 9 substances accounted for 90% of the total
volume of antibiotics, NSAIDs, antihypertensives and
antidepressants, respectively. The proportions of poten-
tially high environmental hazard drugs were 0, 7, 0 and
24%, respectively. Conclusion The prescribing profiles
gave an easily understandable overview for the potential
environmental risk and indication for where improvement
could be made. The 90% profiles were easy and inexpen-
sive to produce using available sales data and may be a
valuable tool to increase the awareness of the environ-
mental aspects among prescribing doctors.
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Impact of findings on practice
• The method can support policy decisions in guidelines
and formularies to recommend less environmentally
harmful pharmaceuticals.
• The method may be useful to improve prescribers’
environmental awareness in their choice of drugs.
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Introduction
Access to clean water is a prerequisite for good health.
Most drugs consumed are subsequently secreted in the
urine, in an unchanged condition or as metabolites. In
urban areas the compounds will reach sewage treatment
plants and sometimes even rivers, lakes and ground water.
Many drug molecules entering sewage treatment plants
will travel through without being degraded or removed by
the cleaning processes. Since the utilization of chemicals,
including pharmaceuticals, is continuously growing, there
is an increasing risk from chemical substances to contam-
inate our food and water supply within the environmental
cycles. Environmental persistence in combination with
bioaccumulation means that pharmaceutical residues are an
increasing problem in diverse environmental compartments
and lead to increased concerns about the ecotoxicity of
pharmaceutical products [1, 2].
A number of studies have been published that show
traces of medicines in water from sewage treatment plants
as well as in lakes and rivers. Medicines that were reported
to have a high concentration in the environment included
various antihypertensives and non-steroidal anti-inflam-
matory drugs (NSAIDs) [3–6]. Some antibiotics and
hormonal preparations have also been detected [7, 8].
Health protection and environmental protection are
societal aims which usually accompany each other. How-
ever, the use of pharmaceuticals shows that both aims can
become contradictory. The Swedish parliament has deter-
mined certain environmental objectives, including; that by
2010 there should be information on the environmental
characteristics for all manufactured or extracted chemical
substances on the market [9]. In pursuance of these envi-
ronmental objectives the Swedish Medical Products
Agency, has identified a number of important actions to be
taken to protect the environment (Table 1) [10].
Stockholm County Council (which has responsibility for
the provision of healthcare in the Swedish metropolitan
region of Stockholm) has the political vision to eliminate
the emission of harmful medical substances to the ground,
sea and air. For most environmentally hazardous medicinal
products in effluent from sewage treatment plants or in
surface water, the current aim is to achieve lower levels in
2011 as compared to 2005 measurements. Consequently,
Stockholm County Council will favour pharmaceuticals
that are not harmful to the environment and work to
influence the pharmaceutical industry to take environ-
mental issues into greater account. This is reflected in the
treatment guidelines issued by the regional Drug and
Therapeutics Committee where drugs are recommended in
preference where the environmental hazard is lower after
the standard tests of safety, efficacy and cost effectiveness
have been taken into account [11].
A classification of environmental hazard for pharma-
ceuticals has been developed by Stockholm County
Council and Apoteket AB (The National Corporation of
Swedish Pharmacies) to express the inherent environmen-
tally damaging characteristics of the active pharmaceutical
ingredient [12, 13]. The classification is based on the
assessment of:
• Persistence (P)—ability to resist degradation in the
aquatic environment
• Bioaccumulation (B)—accumulation in adipose tissue
of aquatic organisms
• Toxicity (T)—the potential to poison aquatic organisms
Each of these characteristics is assigned a numerical
value (0–3). The sum of these values constitutes the PBT
index for the substance. The PBT index can assume values
between 0 and 9.
Since 2005, information about the environmental clas-
sification for the most commonly prescribed medicines in
ambulatory care is printed in a booklet distributed to all
primary healthcare centres and hospital clinics in the
county. The booklet is updated annually and the informa-
tion is also presented on the county’s website for drug
information [14]. However, it is known that simple diffu-
sion or dissemination of printed material is seldom
effective in changing prescribing doctors’ behaviour [15,
16]. To promote effective change it is important to com-
bine evidence based information with other methods such
as interactive education or feedback on prescribing pat-
terns. A method that has been shown to be useful in
implementing guidelines is the Drug Utilization 90%
(DU90%) method providing feedback on the medicines
accounting for 90% of the utilization and adherence to
formulary recommendations within the section. The 90%
level is focusing on the quality of the bulk of the pre-
scribing whilst allowing some leeway for individual
variation [17, 18]. When adding an environmental hazard
dimension, these profiles could provide a useful tool to
increase prescribing doctors’ environmental awareness of
their prescribing practice.
Table 1 Measures regarding environmental aspects of pharmaceuti-
cals proposed by the Swedish Medical Products Agency [10]
Increased basic knowledge
Increased consideration of environmental aspects in the EU
legislation on pharmaceutical products
More and improved environmental risk assessments
Compilation of and electronic access to data
Continuous monitoring of the flows of pharmaceuticals
Education and information to stimulate environmental awareness
Reduce disposal and improve waste-handling of pharmaceutical
products
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Aim of the study
The aim of this study was to develop a method to include
environmental classification for medicines in drug utiliza-
tion data.
Method
Data on sales of medicines in ambulatory care dispensed in
2006 were obtained from Apoteket AB (National Corpora-
tion of Swedish Pharmacies). The data contained both non-
prescription (OTC) sales and all prescriptions dispensed to
the Swedish population, regardless of reimbursement status.
We selected antibiotics (ATC-group J01), drugs for mus-
culoskeletal conditions (NSAIDs including glucosamine)
(M01A), antihypertensive agents (diuretics, beta blockers,
calcium channel blockers and drugs acting on the renin-
angiotensin system) (C03, C07, C08, C09) and antidepres-
sants (N06A) dispensed in the region of Stockholm, Sweden.
The data were analysed by active substance, defined as
all products marketed under a single ATC group [19] and
measured in number of kilograms of the substance. Prod-
ucts containing fixed combinations were divided and
calculated separately for each substance. The total utiliza-
tion for the period for each ATC-group was determined.
We then calculated the number of drugs that accounted for
90% of the total weight in the group (the area under the
curve), i.e. DU90%.
The total amount dispensed was divided by the surface
area in the region excluding the Baltic Sea, i.e. 7,169 km2,
and the population (1.9 million inhabitants) [20]. These
denominators were chosen to asses the intensity of envi-
ronmental emission, both from a geographical and a
population perspective. The drug utilization profiles also
contained the number of Defined Daily Doses (DDDs) and
the number of DDDs per thousand inhabitants per day
(DDD/TID) as a therapeutic measure of exposure [19].
The drugs prescribed were coded into three groups
according to the classification of environmental hazard
developed by Stockholm County Council and Apoteket AB
[12–14]. The classification is based on an evaluation of
each substance’s persistence, potential bioaccumulation
and toxicity. Indexing is provided on a scale of 0–9 and can
be seen as an indication of the active substance’s inherent
danger to the environment based on a sum of numeric
values for the active substance (Table 2).
An active substance that is readily biodegradable, has
low toxicity and does not bioaccumulate receives an
environmental index value of zero. A substance that is not
readily biodegradable, has very high toxicity and is
potentially bio accumulating receives an environmental
index value of 9. Substances with incomplete data have
also been assigned higher values; consequently the index-
ing could also mean a compensation for the lack of data
applying a precautionary principle.
The classification of environmental hazard according to
Stockholm County Council has not been scientifically
validated. It can be regarded as a model elucidating that
drugs can be grouped in a systematic way with reference to
hazard based on available scientific data. However, no
absolute stratification is accomplished by the index value
as these are not mutually comparable. This implies that
comparing two or more drugs with reference to environ-
mental hazard will require going back to the scientific data
describing the hazard of a specific substance.
In this study, we have simplified the classification for
each substance one step further and marked the class in the
drug utilization profiles accordingly. Substances with a
PBT index of 7–9 were made black, 4–6 dark grey and 0–3
light grey, respectively, to illustrate potential high, medium
and low hazard. Drugs without any classification were
presented as striped. The proportions of high/medium/low
risk drugs were assessed by calculating the amount of
kilograms of the substances in each group divided by the
total weight of the 90%-segment.
Results
A total of 16,800 kg of antibiotics, 23,400 kg of NSAIDs,
7,700 kg of various antihypertensive substances and
1,700 kg of antidepressants had been dispensed in the
region during 2006. This corresponds to 8.8, 12.3, 4.0 and
0.9 kg/1000 inhabitants, respectively, or 2.3, 3.3, 1.1 and
0.2 kg/km2.
Table 2 Principles for the assignment of numerical values in the
environmental hazard classification developed by Stockholm County












Note: The PBT denotations used by Stockholm County Council are
not to be mixed up with the well established denotations PBT and
vPvB used for identifying substances according to TGD 2003 [21].
The PBT and vPvB criteria and their application are described by the
Danish EPA [22]
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In the antibiotics group there were a total of 58 sub-
stances. Twelve of these accounted for 90% of the
utilization. Out of these 12, there were six substances, that
included the three most used (phenoxymethylpenicillin,
methenamine and flucloxacillin) that were not classified
(Fig. 1). All the antibiotics that have been classified were
considered having a potential medium environmental
hazard (PBT 4–6). Phenoxymethylpenicillin was the most
used of the antibiotics. It accounted for 6,300 kg, 37.8% of
the total and 4.5 DDD/TID.
In total, 19 different drugs for musculoskeletal condi-
tions were used. Three of them (ibuprofen, glucosamine
and naproxen) accounted for 90% of the utilization
(Fig. 2). Ibuprofen and glucosamine were both available as
OTC during the period. The proportion of non-prescription
sales was 83% and 19%, respectively. Since both ibuprofen
and glucosamine were considered with low environmental
hazard, the profile was rather good from an environmental
perspective (Fig. 2). However, naproxen, the third most
used substance, is considered to be potentially harmful for
the environment (PBT 7–9).
The antihypertensive groups contained a total of 44
different substances, out of which 13 accounted for 90% of
the amount. Two antihypertensive substances, verapamil
and spironolactone, had not yet been classified (Fig. 3).
The most used substance was metoprolol (2,300 kg). Four
substances in the DU90% segment (furosemide, losartan,
propranolol and enalapril) were suggested to be associated
with potential low environmental hazard (PBT 0–3)
(Fig. 3). The remaining classified substances had a poten-
tial medium environmental hazard (PBT 4–6).
A total of 22 different antidepressants were used in the
study period. All nine antidepressants within the DU90%
segment had an environmental classification (Fig. 4). No
single substance used was considered to have a potential low
environmental risk. Two substances (citalopram and mirt-
azapine), together accounted for one quarter of the total
volume within the DU90% segment and were considered to
be associated with a potential high environmental hazard.
Discussion
The results show the feasibility of combining sales statis-
tics of drugs with classification of environmental hazard.
The proposed method may be a useful tool to bring envi-
ronmental aspects into the prescribing decisions of
healthcare professionals. The DU90% profiles were inex-
pensive to produce and were based on readily available
data for dispensed medicines. The sales data were complete
for the therapeutic areas selected including all drugs dis-
pensed in ambulatory care regardless of reimbursement and
prescription status. Further refinement may be done
depending on the data available. It is possible to produce
Substance (DDD) Kg % TOT Kg/km2 Kg/1000 
inhabitant
DDD DDD/TID
1 Phenoxymethylpenicillin 2 g 6 348 37,8% 0,89 3,3 3 174 007 4,5
2 Methenamine 2 g 2 833 16,9% 0,40 1,5 1 416 679 2,0
3 Flucloxacillin 2 g 1 946 11,6% 0,27 1,0 972 770 1,4
4 Amoxicillin 1 g 1 400 8,3% 0,20 0,7 1 400 320 2,0
5 Ciprofloxacin 0.5g/1g 567 3,4% 0,08 0,3 571 616 0,8
6 Lymecycline 0.6 g 538 3,2% 0,07 0,3 895 900 1,3
7 Erythromycin 1g/2g 425 2,5% 0,06 0,2 379 042 0,5
8 Cefadroxil 2 g 319 1,9% 0,04 0,2 159 445 0,2
9 Sulfamethoxazole 2 g 256 1,5% 0,04 0,1 160 214 0,2
10 Clindamycin 1.2g/1.8g 254 1,5% 0,04 0,1 206 689 0,3
11 Tetracycline 1 g 233 1,4% 0,03 0,1 232 671 0,3
12 Trimethoprim 0.4 g 231 1,4% 0,03 0,1 533 939 0,8
15 350 91,3% 2,14 8,0
1 464 8,7% 0,20 0,8
16 813 100,0% 2,35 8,8
DU 90%       1 - 12
    13 - 58
TOTAL       1 - 58











DU 90% = 
12 substances
Percentage of environmentally classified drugs: 20
Potential high environmental hazard PBT 7-9: 0
Potential medium environmental hazard PBT 4-6: 20
Potential low environmental hazard PBT 1-3: 0
Not classified: 80
7
Fig. 1 DU90% profile for
antibiotics (J01) for Stockholm
County, Sweden 2006
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similar prescribing profiles for primary care practices,
hospital clinics or populations based on various population
levels from municipalities up to a region or even a country.
The selection may be made for a certain pharmacological
group (ATC), but environmental risk profiles may also be
produced for the whole range of pharmaceutical products
prescribed to provide an overall environmental risk
assessment. These profiles represent one way to find the
most important areas of improvement. However, profiles
restricted to a certain pharmacological group are more
intuitive from a therapeutic point of view since in this
scenario the drugs may be interchangeable.
Rational drug therapy can be defined as ‘‘Patients receive
medication appropriate to their medical needs, in doses
meeting their own individual requirements, for an adequate
period of time and at the lowest cost to them and the
community’’ [23]. We propose that environmental concern
should be included in this definition. However, such envi-
ronmental concern should always be considered in
combination with other important aspects as efficacy, safety
Substance (DDD) Kg % TOT Kg/km2 Kg/1000 
inhabitant
DDD DDD/TID
1 Ibuprofen 1.2 g 13 460 57,4% 1,88 7,0 11 327 831 16,2
2 Glucosamine 1.5 g 6 639 28,3% 0,93 3,5 4 426 193 6,3
3 Naproxen 0.5 g 1 554 6,6% 0,22 0,8 3 107 301 4,5
21 653 92,4% 3,02 11,3
1 793 7,6% 0,25 0,9
23 446 100,0% 3,27 12,3
DU 90%       1 - 3
    4 - 19
TOTAL       1 - 19










DU 90% = 3 
substances
Percentage of environmentally classified drugs: 100
Potential high environmental hazard PBT 7-9: 7
Potential medium environmental hazard PBT 4-6: 0
Potential low environmental hazard PBT 1-3: 93
Not classified: 0
2 3





Substance (DDD) Kg % TOT Kg/km2 Kg/1000 
inhabitant
DDD DDD/TID
1 Metoprolol 0.15 g 2 308 30,0% 0,32 1,2 15 891 268 22,8
2 Furosemide 40 mg 1 059 13,8% 0,15 0,6 26 474 862 37,9
6,01670 034 73,080,0%2,7755gm 57lolonetA3
4 Hydrochlorothiazide 25 mg 556 7,2% 0,08 0,3 17 929 096 25,7
5 Irbesartan 0.15 g 524 6,8% 0,07 0,3 2 930 088 4,2
6 Losartan 50 mg 487 6,3% 0,07 0,3 8 974 519 12,9
7 Valsartan 80 mg 273 3,5% 0,04 0,1 2 910 515 4,2
8 Verapamil 0.24 g 255 3,3% 0,04 0,1 1 072 476 1,5
2,2516 565 11,030,0%3,3052g 61.0lolatoS9
10 Diltiazem 0.24 g 243 3,2% 0,03 0,1 1 014 316 1,5
11 Enalapril 10 mg 196 2,6% 0,03 0,1 18 171 392 26,0
12 Propranolol 0.16 g 191 2,5% 0,03 0,1 1 192 694 1,7
13 Spironolactone 75 mg 182 2,4% 0,03 0,1 2 422 197 3,5
7 082 92,1% 0,99 3,7
605 7,9% 0,08 0,3
7 687 100,0% 1,07 4,0
DU 90%       1 - 13
    14 - 44
TOTAL       1 - 44













Potential high environmental hazard PBT 7-9: 0
Potential medium environmental hazard PBT 4- 67
Potential low environmental hazard PBT 1-3: 27
Not classified: 6
Percentage of environmentally classified drugs:Fig. 3 DU90% profile for
antihypertensives (C03, C07,
C08 and C09) for Stockholm
County, Sweden 2006
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and cost-effectiveness to optimize drug therapy. We believe
that drug utilization profiles focusing on environmental
hazard have great value in pharmaceutical policymaking,
e.g. as a basis for drug selection to formularies and guide-
lines, such as the regional Drug and Therapeutics
Committee guidelines used in Stockholm [11].
It is important to improve the utilization of antibiotics. It
has been shown that the total utilization of antibiotics is
correlated to antimicrobial resistance [24]. The WHO has
pointed out antimicrobial resistance as a main concern for
global health [25]. Studies have shown a considerable
variation between countries of the utilization of antibiotics
with Sweden reporting a relatively low utilization [26]. In
our study, the choice of antibiotic substances seemed to be
rational from a therapeutic point of view since the most
used antibiotic was the narrow spectrum phenoxymethyl-
penicillin. The environmental aspects are uncertain since
the most used antibiotics were not classified. Further efforts
need to be taken to assess the environmental hazard for
those substances and drugs of other therapeutic areas where
no data is currently available.
The utilization of NSAIDs seemed to be appropriate
from an environmental point of view. Ibuprofen, the most
used NSAID, should be the preferred choice among
NSAIDs also due to its relatively low gastrointestinal
toxicity [27]. However, questions may be raised about the
total level of use of NSAIDs and the high use of gluco-
samine. The latter has a poor therapeutic value and should
consequently not be used, although it seems to be relatively
harmless for the environment [28].
There was no obvious potential for environmental
improvement in the utilization of antihypertensives. The
different medicines represent different drug classes that are
all recommended for certain patient groups. Furthermore,
the drugs are not only used for the treatment of hyperten-
sion but for a variety of other medical conditions, e.g. heart
failure, angina pectoris and secondary prevention after
myocardial infarction. Although the profile indicates that
furosemide, losartan, propranolol and enalapril may be
preferable from an environmental point of view, these
drugs may not be recommended as alternatives due to
differences in licensed indication, safety profile and cost-
effectiveness compared to the alternatives. However,
questions may be raised about the high utilization of beta
blockers, since their effectiveness has been under discus-
sion in recent years [29]. A higher use of ACE-inhibitors
and thiazides (where therapeutically indicated) may
therefore be recommended since they have a broad range of
licensed indications, a comparatively low price and a good
environmental profile. Also, it is important to emphasize
that many reports have shown that there is an under
treatment of hypertension [30].
Since the drug potency varies, some drugs with a high
utilization in the population, e.g. the calcium channel
blockers felodipine and amlodipine, generated low amounts
when measured in kilograms and thus did not appear within
the DU90% segment for the antihypertensives. This may to
some extent reduce the external validity of the method for
prescribers. A potential solution could be to extend the
cut off point to, e.g., 95%. It can also be handled by
Substance (DDD) Kg % TOT Kg/km2 Kg/1000 
inhabitant
DDD DDD/TID
1 Sertraline 50 mg 455 27,4% 0,06 0,24 9 105 589 13,0
2 Venlafaxine 0.1 g 381 22,9% 0,05 0,20 3 812 492 5,5
3 Citalopram 20 mg 269 16,2% 0,04 0,14 13 474 641 19,3
4 Mirtazapine 30 mg 105 6,3% 0,01 0,05 3 502 759 5,0
5 Amitriptyline 75 mg 95 5,7% 0,01 0,05 1 262 560 1,8
6 Fluoxetine 20 mg 65 3,9% 0,01 0,03 3 232 951 4,6
7 Clomipramine 0.1 g 62 3,7% 0,01 0,03 621 221 0,9
8 Duloxetine 60 mg 62 3,7% 0,01 0,03 1 031 893 1,5
9 Moclobemide 0.3 g 42 2,5% 0,01 0,02 138 892 0,2
1 536 92,4% 0,21 0,80
127 7,6% 0,02 0,07
1 663 100,0% 0,23 0,87
DU 90%       1 - 9
    10 - 22
TOTAL       1 - 22











DU 90% = 
9 substances
Percentage of environmentally classified drugs:
Potential high environmental hazard PBT 7-9: 24
Potential medium environmental hazard PBT 4- 76
Potential low environmental hazard PBT 1-3: 0
Not classified: 0
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complementing the DU90% environmental profiles with
traditional profiles using DDD as the measure of exposure.
All antidepressants were environmentally classified, two
substances being associated with a potentially high envi-
ronmental risk. There is a limited potential for improvement
in the utilization of antidepressant drugs, since there are no
antidepressants associated with a potential low environ-
mental risk. However, citalopram may be substituted with
other serotonin selective reuptake inhibitors since they have
shown to be equally effective [31].
As discussed above, the environmental prescribing pro-
files highlighted several areas for improvement. However,
the prescribing profiles should be applied as a recommen-
dation for improvement on a population level. It is important
to emphasize that rational drug therapy implies a rational
decision for each individual patient taking into account the
efficacy, tolerability, and potential for interactions of each
specific drug. Consequently, there may be reasons to deviate
from general guidelines for certain patients. The credibility
of the proposed method is dependent on the validity of the
DU90% method as well as validity of the classification of
environmental hazard. The DU90% method has been vali-
dated in a large number of studies and is increasingly used in
many countries to assess the quality of prescribing [32]. The
low validity of the classification model adopted in this study
will hamper a more general application of the proposed
method. Nevertheless, being knowledgeable about its
drawbacks it can still serve as a driver for a better envi-
ronmental outcome of drug use.
The legislation for new drugs to be approved for use in
humans has been continuously strengthened during the last
decades. The thalidomide tragedy tightened the require-
ments to provide safety data and in recent years, most
countries require manufacturers to provide evidence that
new drugs are more cost-effective than existing agents to
achieve reimbursement. Environmental concern does not
yet influence any approval or reimbursement decision for
human medicines [33]. This may change in the future.
Regardless of how this development will proceed, robust
and convenient methods will still be needed to guide
healthcare providers to use those medicines available on
the market more rationally. This does not imply a ‘one size
fit all’ thinking but more an ‘added value’ to the individual
drug choice by a systematic inclusion of scientifically
based evidence that can be generally applied. The method
we propose supports these aims of bringing the environ-
mental dimension into the drug selection process.
Conclusion
The DU90% environmental profiles gave an easily under-
standable overview of the potential prevailing
environmental risk and potentials for improvement in drug
prescribing. The profiles were easy and inexpensive to
produce using available sales data, and may be a valuable
tool to increase the awareness of an environmental impact
of the prescribing decision.
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